Name: CELLECTIS (ALCLS) Stock
Brand: CELLECTIS
Rating: 6 (3 reviews)

Question 1

Can you describe the business of CELLECTIS?

Accepted Answer

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Question 2

What is the stock price of CELLECTIS today?

Accepted Answer

The current stock price of ALCLS.PA is 3.86 EUR. The price decreased by -2.15% in the last trading session.

Question 3

Does ALCLS stock pay dividends?

Accepted Answer

ALCLS.PA does not pay a dividend.

Question 4

What is the ChartMill technical and fundamental rating of ALCLS stock?

Accepted Answer

ALCLS.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.

Question 5

What is the expected growth for ALCLS stock?

Accepted Answer

The Revenue of CELLECTIS (ALCLS.PA) is expected  to grow  by 45.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.

Question 6

What is CELLECTIS worth?

Accepted Answer

CELLECTIS (ALCLS.PA) has a market capitalization of 387.26M EUR. This makes ALCLS.PA a Small Cap stock.

CELLECTIS (ALCLS.PA) Stock Price, Forecast & Analysis

ALCLS.PA Latest News, Press Relases and Analysis